Dr. Fritiof Pontén, CEO of QureTech Bio—one of Sweden's youngest biotech companies—talks with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about QureTech's business foundation, its novel technology for disabling bacteria and how the company's products could be a solution to the global challenge of antibiotic resistance. QureTech is developing a new class of antibacterial agents that may have broad-spectrum activity against Chlamydia and other pathogens. Termed virulence blockers, these agents selectively disarm the pathogenic capability of certain bacteria, without affecting normal bacterial flora, decreasing the selection pressure for resistance development.
